[18F]AlF-NOTA-FAPI-04 PET/CT for Predicting Pathologic Response of Resectable Esophageal Squamous Cell Carcinoma to Neoadjuvant Camrelizumab and Chemotherapy: A Phase II Clinical Trial

Yinjun Dong; Zhendan Wang; Xinying Hu; Yuhong Sun; Jingjie Qin; Qiming Qin; Shuguang Liu; Shuanghu Yuan; Jinming Yu; Yuchun Wei

doi:10.2967/jnumed.124.268557

Research ArticleClinical Investigation

[¹⁸F]AlF-NOTA-FAPI-04 PET/CT for Predicting Pathologic Response of Resectable Esophageal Squamous Cell Carcinoma to Neoadjuvant Camrelizumab and Chemotherapy: A Phase II Clinical Trial

Yinjun Dong, Zhendan Wang, Xinying Hu, Yuhong Sun, Jingjie Qin, Qiming Qin, Shuguang Liu, Shuanghu Yuan, Jinming Yu and Yuchun Wei

Journal of Nuclear Medicine November 2024, 65 (11) 1702-1709; DOI: https://doi.org/10.2967/jnumed.124.268557

Yinjun Dong

1Department of Esophageal Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Zhendan Wang

2Department of Thoracic Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Xinying Hu

3Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Yuhong Sun

4Department of Pathology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China; and

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jingjie Qin

3Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Qiming Qin

1Department of Esophageal Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Shuguang Liu

1Department of Esophageal Surgery, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Shuanghu Yuan

3Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China;

5Department of Radiation Oncology, Division of Life Sciences and Medicine, First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jinming Yu

3Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Yuchun Wei

3Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China;

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Supplemental
Info & Metrics
PDF

Data supplements

Supplemental Data

Files in this Data Supplement:

Supplemental Data

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 65, Issue 11

November 1, 2024

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following [18F]AlF-NOTA-FAPI-04 PET/CT for Predicting Pathologic Response of Resectable Esophageal Squamous Cell Carcinoma to Neoadjuvant Camrelizumab and Chemotherapy: A Phase II Clinical Trial

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

[¹⁸F]AlF-NOTA-FAPI-04 PET/CT for Predicting Pathologic Response of Resectable Esophageal Squamous Cell Carcinoma to Neoadjuvant Camrelizumab and Chemotherapy: A Phase II Clinical Trial

Yinjun Dong, Zhendan Wang, Xinying Hu, Yuhong Sun, Jingjie Qin, Qiming Qin, Shuguang Liu, Shuanghu Yuan, Jinming Yu, Yuchun Wei

Journal of Nuclear Medicine Nov 2024, 65 (11) 1702-1709; DOI: 10.2967/jnumed.124.268557

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

[¹⁸F]AlF-NOTA-FAPI-04 PET/CT for Predicting Pathologic Response of Resectable Esophageal Squamous Cell Carcinoma to Neoadjuvant Camrelizumab and Chemotherapy: A Phase II Clinical Trial

Yinjun Dong, Zhendan Wang, Xinying Hu, Yuhong Sun, Jingjie Qin, Qiming Qin, Shuguang Liu, Shuanghu Yuan, Jinming Yu, Yuchun Wei

Journal of Nuclear Medicine Nov 2024, 65 (11) 1702-1709; DOI: 10.2967/jnumed.124.268557

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Supplemental
Info & Metrics
PDF

PubMed
Google Scholar

Cited By...

No citing articles found.

Google Scholar

Keywords

esophageal squamous cell carcinoma
FAPI
neoadjuvant
pathologic response

Main menu

User menu

Search

[¹⁸F]AlF-NOTA-FAPI-04 PET/CT for Predicting Pathologic Response of Resectable Esophageal Squamous Cell Carcinoma to Neoadjuvant Camrelizumab and Chemotherapy: A Phase II Clinical Trial

Data supplements

Supplemental Data

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords